Insider Selling: MannKind Co. (NASDAQ:MNKD) EVP Sells $109,682.42 in Stock

MannKind Co. (NASDAQ:MNKD) EVP David Thomson sold 23,537 shares of the stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $4.66, for a total value of $109,682.42. Following the completion of the transaction, the executive vice president now owns 873,616 shares in the company, valued at $4,071,050.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

MannKind Stock Performance

Shares of NASDAQ:MNKD opened at $4.82 on Friday. The stock’s fifty day simple moving average is $4.43 and its two-hundred day simple moving average is $3.96. MannKind Co. has a 1-year low of $3.17 and a 1-year high of $5.75. The stock has a market cap of $1.31 billion, a PE ratio of 160.72 and a beta of 1.34.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.02. The business had revenue of $66.26 million for the quarter, compared to analysts’ expectations of $60.55 million. MannKind had a negative return on equity of 3.35% and a net margin of 3.78%. The business’s revenue was up 63.1% on a year-over-year basis. During the same period last year, the business earned ($0.04) EPS. On average, sell-side analysts forecast that MannKind Co. will post 0.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MannKind

A number of hedge funds have recently made changes to their positions in MNKD. Commonwealth Equity Services LLC raised its stake in shares of MannKind by 7.6% during the 3rd quarter. Commonwealth Equity Services LLC now owns 95,432 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 6,760 shares during the period. Raymond James & Associates increased its holdings in MannKind by 19.2% in the 3rd quarter. Raymond James & Associates now owns 335,826 shares of the biopharmaceutical company’s stock worth $1,387,000 after acquiring an additional 54,046 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in MannKind by 32.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 61,590 shares of the biopharmaceutical company’s stock worth $254,000 after acquiring an additional 14,941 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in MannKind by 4.7% in the 3rd quarter. Teacher Retirement System of Texas now owns 75,049 shares of the biopharmaceutical company’s stock worth $310,000 after acquiring an additional 3,402 shares during the last quarter. Finally, Great Valley Advisor Group Inc. purchased a new stake in MannKind in the 3rd quarter worth about $54,000. 49.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on MNKD shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.50 target price on shares of MannKind in a report on Thursday, May 9th. Wedbush restated an “outperform” rating and set a $10.00 price objective on shares of MannKind in a research note on Wednesday, February 28th.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.